These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22355307)

  • 1. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
    Lataillade M; Chiarella J; Yang R; DeGrosky M; Uy J; Seekins D; Simen B; St John E; Moreno E; Kozal M
    PLoS One; 2012; 7(2):e30118. PubMed ID: 22355307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of minor drug-resistant viral variants in patients experiencing virological failure (VF) on a first-line regimen in Fujian Province by high-throughput sequencing.
    Deng Y; Wu S; Qiu L; Yan Y
    Ann Palliat Med; 2021 Jul; 10(7):7775-7785. PubMed ID: 34353064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
    Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
    Ross LL; Weinberg WG; DeJesus E; Fischl MA; Horton JH; Pappa KA; Lancaster CT; Pakes GE; Smith KY
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):407-17. PubMed ID: 20380480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
    Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
    AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.
    Vandenhende MA; Bellecave P; Recordon-Pinson P; Reigadas S; Bidet Y; Bruyand M; Bonnet F; Lazaro E; Neau D; Fleury H; Dabis F; Morlat P; Masquelier B
    PLoS One; 2014; 9(1):e86771. PubMed ID: 24475178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
    Lataillade M; Chiarella J; Yang R; Schnittman S; Wirtz V; Uy J; Seekins D; Krystal M; Mancini M; McGrath D; Simen B; Egholm M; Kozal M
    PLoS One; 2010 Jun; 5(6):e10952. PubMed ID: 20532178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
    Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
    BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
    Lambert-Niclot S; Grude M; Chaix ML; Charpentier C; Reigadas S; Le Guillou-Guillemette H; Rodallec A; Amiel C; Maillard A; Dufayard J; Mourez T; Mirand A; Guinard J; Montes B; Vallet S; Marcelin AG; Descamps D; Flandre P; Delaugerre C; Morand-Joubert L;
    J Antimicrob Chemother; 2018 Aug; 73(8):2147-2151. PubMed ID: 29718247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China.
    Chen X; Zou X; He J; Zheng J; Chiarella J; Kozal MJ
    PLoS One; 2016; 11(2):e0149215. PubMed ID: 26895182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
    d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
    Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
    Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
    BMC Infect Dis; 2009 Sep; 9():154. PubMed ID: 19751502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
    Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D
    Clin Drug Investig; 2014 Apr; 34(4):287-96. PubMed ID: 24557728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
    Rhee SY; Jordan MR; Raizes E; Chua A; Parkin N; Kantor R; Van Zyl GU; Mukui I; Hosseinipour MC; Frenkel LM; Ndembi N; Hamers RL; Rinke de Wit TF; Wallis CL; Gupta RK; Fokam J; Zeh C; Schapiro JM; Carmona S; Katzenstein D; Tang M; Aghokeng AF; De Oliveira T; Wensing AM; Gallant JE; Wainberg MA; Richman DD; Fitzgibbon JE; Schito M; Bertagnolio S; Yang C; Shafer RW
    PLoS One; 2015; 10(12):e0145772. PubMed ID: 26717411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.